# Diamyd Medical > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/diamydmedical). ## Overview Diamyd Medical is a Swedish biopharmaceutical company focused on precision medicine for type 1 diabetes. Its core work centers on developing antigen-specific immunotherapies, led by the investigational product Diamyd® (rhGAD65/alum), alongside in-house manufacturing of the recombinant GAD65 active ingredient in Umeå. ## Products & services • Diamyd® (rhGAD65/alum) precision medicine therapy • Phase 3 clinical development in type 1 diabetes • Recombinant GAD65 manufacturing • Precision medicine platform for genetically defined patients • In-house biomanufacturing and analytical capabilities - **Clinical-stage therapeutics** (70%) — Investigational drug candidates and clinical programs for type 1 diabetes. - **Biomanufacturing** (20%) — Internal production of recombinant GAD65 active pharmaceutical ingredient. - **Research and platform development** (10%) — Precision medicine research, biomarker strategy, and supporting R&D activities. - Diamyd® (rhGAD65/alum) precision medicine therapy - Phase 3 clinical development in type 1 diabetes - Recombinant GAD65 manufacturing - Precision medicine platform for genetically defined patients - In-house biomanufacturing and analytical capabilities ## Customers Diamyd Medical does not sell a broad commercial product portfolio; its main end users are patients with type 1 diabetes, accessed through clinical trials, future prescribing physicians, and healthcare systems. In the nearer term, its direct counterparties are clinical trial sites, research collaborators, and potential licensing or commercialization partners. The company’s manufacturing capability also creates a potential customer base for external biomanufacturing projects. - **Type 1 diabetes patients** (primary) — Patients in clinical studies who receive or are evaluated for Diamyd® to preserve endogenous insulin production. - **Clinical trial sites and investigators** (primary) — Hospitals and clinics that administer trials, collect samples, and generate the clinical data needed for approval. - **Pharmaceutical licensing partners** (secondary) — Potential partners that may license Diamyd® or support commercialization in selected markets. - **External biomanufacturing customers** (emerging) — Third parties that may use the Umeå facility for biological compound production. - Patients with type 1 diabetes enrolled in clinical trials - Clinical investigators and trial sites running DIAGNODE-3 - Healthcare systems and physicians for future commercialization - Pharma partners for licensing or co-development - External biomanufacturing customers for biological compounds ## Geography Diamyd Medical is headquartered in Stockholm and operates a manufacturing facility in Umeå, Sweden. Its clinical development work spans the United States and Europe, and its patent estate extends across multiple regions including Europe, the US, Japan, South Korea, China, Canada, and others. Geography matters because the company’s trial execution, regulatory pathway, and future commercialization opportunities are tied to these markets. - **Sweden** (100%) — Corporate headquarters and manufacturing base are in Sweden. - Headquartered in Stockholm, Sweden - Manufacturing and API production in Umeå, Sweden - DIAGNODE-3 clinical program in the United States and Europe - Patent protection across the US, Europe, Asia, and other markets - Future commercialization depends on selected regional approvals ## Strategy Diamyd Medical’s strategy is built around advancing Diamyd® through registrational clinical development and using precision medicine to target genetically defined patient groups. The company also emphasizes patent protection, regulatory designations, and in-house manufacturing to support future commercialization and control supply. Partnerships with patient organizations and potential licensing arrangements are part of the route to market. - **Complete and read out DIAGNODE-3** (short-term) — The Phase 3 program is the key clinical and regulatory value driver. - **Build precision-medicine positioning** (medium-term) — Genetically defined patient selection can improve clinical differentiation and commercial focus. - **Secure manufacturing and supply control** (medium-term) — Owning API production reduces dependence on external suppliers and supports scalability. - **Protect and extend intellectual property** (long-term) — Patent coverage underpins future licensing and commercialization economics. - Advance DIAGNODE-3 toward regulatory readout and approval - Target genetically defined type 1 diabetes subpopulations - Use patent protection to support commercialization leverage - Maintain in-house GAD65 manufacturing control - Pursue licensing and selected-market sales opportunities ## Risks Diamyd Medical faces the typical risks of a clinical-stage biotech company: trial failure, regulatory setbacks, and uncertainty around commercialization. Its value also depends on intellectual property protection, partner execution, manufacturing reliability, and continued access to financing while development programs remain pre-commercial. - **Drug development failure** [critical] — The company depends on positive clinical data from DIAGNODE-3 and related studies. - **Regulatory approval risk** [high] — Approval depends on FDA and other authority decisions, which can change timelines or requirements. - **Intellectual property risk** [high] — Patent scope, validity, and enforceability are central to future commercialization and licensing. - **Financing risk** [high] — Clinical-stage biotech companies often require external capital before revenues are established. - **Manufacturing and supply-chain risk** [medium] — The company relies on successful scale-up and reliable GMP production of recombinant GAD65. - Clinical trial outcomes may not meet efficacy or safety expectations - Regulatory decisions can delay or block approval pathways - IP disputes could weaken patent protection or licensing value - Financing needs are high before product commercialization - Manufacturing or partner failures could delay development ## Accounting Diamyd Medical’s reported results are shaped by clinical-stage biotech accounting, where research and development costs are expensed as incurred and public funding is recognized only when conditions are met. Investors should also watch lease accounting for the Umeå facility, valuation of share-based incentives, and any impairment or fair-value judgments tied to capitalized assets and financial instruments. - **Research and development expense recognition** — Timing of DIAGNODE-3 and other studies drives expense volatility - **Public funding recognition** — Can create uneven recognition across periods - **Lease accounting** — Affects EBITDA-like measures, leverage, and depreciation/interest split - **Share-based compensation** — Impacts operating costs and equity dilution - **Foreign currency translation** — Can affect reported profit and balance sheet values - R&D is expensed as incurred, affecting reported operating loss timing - Public funding is recognized only when receipt and conditions are probable - Lease accounting affects facility-related balance sheet and expense timing - Share-based compensation creates non-cash personnel expense - Foreign currency items can move results through translation gains/losses --- *Last updated: 2026-08-11T04:04:51.757162+00:00*